Successful Treatment of EBV PTLD with CNS Lymphomas with the Monoclonal Anti-CD20 Antibody Rituximab

被引：18

作者：

Kordelas, Lambros ^{[1
]}

Trenschel, Rudolf ^{[1
]}

Koldehoff, Michael ^{[1
]}

Elmaagacli, Ahmet ^{[1
]}

Beelen, Dietrich W. ^{[1
]}

机构：

[1] Univ Hosp Essen, Dept Bone Marrow Transplantat, Essen, Germany

来源：

ONKOLOGIE | 2008年 / 31卷 / 12期

关键词：

EBV; PTLD; Anti-CD20 antibody rituximab; Allogeneic stem cell transplantation;

D O I：

10.1159/000165057

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Posttransplant lymphoproliferative disease (PTLD) is a life-threatening complication after allogeneic hematopoietic stem cell (HSCT) or solid organ transplantation. The majority of PTLD are associated with the Epstein-Barr virus (EBV). PTLD may involve several organs like liver, lungs, kidney, spleen, and small intestine. PTLD with central nervous system (CNS) involvement only has been reported in very few cases so far. Case Reports: We here describe 2 cases who 7 and 12 months after HSCT developed EBV PTLD with CNS lymphomas only. The efficacy of therapy was monitored by magnetic resonance imaging, EBV replication, light chain detection, and the clinical course. Both patients responded very well to the intravenous administration of the monoclonal anti-CD20 antibody rituximab. Conclusion: These 2 case reports illustrate that in EBV PTLD with CNS lymphomas, the systemic administration of rituximab only may prove effective.

引用

页码：691 / 693

页数：3

共 21 条

[1] Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders:: results of a prospective multicenter phase 2 study [J].

Choquet, S ;

Leblond, V ;

Herbrecht, R ;

Socié, G ;

Stoppa, AM ;

Vandenberghe, P ;

Fischer, A ;

Morschhauser, F ;

Salles, G ;

Feremans, W ;

Vilmer, E ;

Peraldi, MN ;

Lang, P ;

Lebranchu, Y ;

Oksenhendler, E ;

Garnier, JL ;

Lamy, T ;

Jaccard, A ;

Ferrant, A ;

Offner, F ;

Hermine, O ;

Moreau, A ;

Fafi-Kremer, S ;

Morand, P ;

Chatenoud, L ;

Berriot-Varoqueaux, N ;

Bergougnoux, L ;

Milpied, N .

BLOOD, 2006, 107 (08) :3053-3057

[2] Epstein-Barr virus (EBV) reactivation in allogeneic stem-cell transplantation:: Relationship between viral load, EBV-specific T-cell reconstitution and rituximab therapy [J].

Clave, E ;

Agbalika, F ;

Bajzik, V ;

de Latour, RP ;

Trillard, M ;

Rabian, C ;

Scieux, C ;

Devergie, A ;

Socié, G ;

Ribaud, P ;

Adès, L ;

Ferry, C ;

Gluckman, E ;

Charron, D ;

Esperou, H ;

Toubert, A ;

Moins-Teisserenc, H .

TRANSPLANTATION, 2004, 77 (01) :76-84

[3]

Curtis RE, 1999, BLOOD, V94, P2208

[4] Post-transplant lymphoproliferative disorders [J].

Gottschalk, S ;

Rooney, CM ;

Heslop, HE .

ANNUAL REVIEW OF MEDICINE, 2005, 56 :29-44

[5] Pre-emptive therapy with rituximab for prevention of Epstein-Barr virus-associated lymphoproliferative disease after hematopoietic stem cell transplantation [J].

Gruhn, B ;

Meerbach, A ;

Häfer, R ;

Zell, R ;

Wutzler, P ;

Zintl, F .

BONE MARROW TRANSPLANTATION, 2003, 31 (11) :1023-1025

[6] Anti-CD20 monoclonal antibody (Rituximab) and cidofovir as successful treatment of an EBV-associated lymphoma with CNS involvement [J].

Hänel, M ;

Fiedler, F ;

Thorns, C .

ONKOLOGIE, 2001, 24 (05) :491-494

[7] CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation [J].

Kuehnie, I ;

Huls, MH ;

Liu, ZS ;

Semmelmann, M ;

Krance, RA ;

Brenner, MK ;

Rooney, CM ;

Heslop, HE .

BLOOD, 2000, 95 (04) :1502-1505

[8] Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: A retrospective analysis on 32 patients [J].

Milpied, N ;

Vasseur, B ;

Parquet, N ;

Garnier, JL ;

Antoine, C ;

Quartier, P ;

Carret, AS ;

Bouscary, D ;

Faye, A ;

Bourbigot, B ;

Reguerre, Y ;

Stoppa, AM ;

Bourquard, P ;

de Ligny, BH ;

Dubief, F ;

Mathieu-Boue, A ;

Leblond, V .

ANNALS OF ONCOLOGY, 2000, 11 :113-116

[9] Epstein-Barr virus-associated post-transplant lymphoproliferative disease with central nervous system involvement after unrelated allogeneic hematopoietic stem cell transplantation [J].

Nozzoli, C ;

Bartolozzi, B ;

Guidi, S ;

Orsi, A ;

Vannucchi, AM ;

Leoni, F ;

Bosi, A .

LEUKEMIA & LYMPHOMA, 2006, 47 (01) :167-169

[10] Effect of anti-CD 20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD) [J].

Oertel, SHK ;

Verschuuren, E ;

Reinke, P ;

Zeidler, K ;

Papp-Váry, M ;

Babel, N ;

Trappe, RU ;

Jonas, S ;

Hummel, M ;

Anagnostopoulos, I ;

Dörken, B ;

Riess, HB .

AMERICAN JOURNAL OF TRANSPLANTATION, 2005, 5 (12) :2901-2906

← 1 2 3 →